A Phase 1 interventional study of Bulevirtide (BLV) in Chronic Hepatitis D Infection, sponsored by Gilead Sciences. Completed at 9 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.
This study's enrollment of 41 is below the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.
Browse Hepatitis D, Chronic studies →Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
All Individuals:
Individuals with Renal Impairment (RI):
Estimated (eGFR) must be the following (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Inker 2021)) based on serum creatinine as measured at the screening evaluation:
Matched Control Individuals:
Key Exclusion Criteria:
All Individuals:
Individuals with RI:
Matched Control Individuals:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe renal impairment (RI) \[estimated glomerular filtration rate (eGFR) ≥ 15 to ≤ 29 mL/min/1.73 m\^2\] will receive bulevirtide (BLV) 2 mg, administered subcutaneously (SC), once daily (QD), for 6 days.
Drug: Bulevirtide (BLV)
Participants with normal renal function (matched control group) \[eGFR ≥ 90 mL/min/1.73 m\^2\] will receive BLV 2 mg, administered SC, QD, for 6 days.
Drug: Bulevirtide (BLV)
Participants with severe RI \[eGFR ≥ 15 to ≤ 29 mL/min/1.73 m\^2\] will receive BLV 10 mg, administered SC, QD, for 6 days.
Drug: Bulevirtide (BLV)
Participants with normal renal function (matched control group) \[eGFR ≥ 90 mL/min/1.73 m\^2\] will receive BLV 10 mg, administered SC, QD, for 6 days.
Drug: Bulevirtide (BLV)
Administered via subcutaneous (SC) injections
Also known as: Hepcludex®, Myrcludex B
Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau
AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state at Day 6.
Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
PK Parameter for BLV: Cmax ss
Cmax is defined as the maximum observed concentration of drug at steady state at Day 6.
Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
PK Parameter for BLV: AUC0-24
AUC0-24 is defined as the concentration of drug over time between time 0 hour and time 24 hours.
Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
PK Parameter for BLV: Cmax
Cmax is defined as the maximum observed concentration of drug.
Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
PK Parameter for BLV: Tmax
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
PK Parameter for BLV: t1/2
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
PK Parameter for BLV: CLss/F
CLss/F is defined as the apparent clearance at steady state at Day 6. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.
Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
PK Parameter for BLV: Vss/F
Vss/F is defined as the apparent volume of distribution at steady state at Day 6.
Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Pharmacodynamic (PD) Parameter for Total Bile Acids (BA): Cmax
The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. Cmax is defined as the maximum observed concentration of total BA. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.
Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
PD Parameter for Total BA: AUC0-24
The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. AUC0-24 is defined as the concentration of total BA over time between time 0 hour and time 24 hours. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.
Time frame: Days 1 and 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
PD Parameter for Total BA: NetAUC
The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. NetAUC is defined as positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.
Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or if the AE onset date was the same as the date of study drug start date then the AE onset time must have been on or after the study drug start time. If the AE onset time was missing when the start dates was the same, the AE was considered treatment emergent.and/or any AEs leading to premature discontinuation of study drug.
Time frame: Up to 36 days
Percentage of Participants Experiencing Laboratory Abnormalities
A treatment-emergent laboratory abnormality was any value that was outside the reference range at any time post baseline up to and including the date of last study drug dose plus 30 days. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death. Participants with at least a 1 grade increased from baseline for an individual laboratory test where the maximum post baseline laboratory abnormality was grade 1 or higher and grade 3 or higher were reported. The maximum post baseline toxicity grade across all tests for an individual participant was used in analysis.
Time frame: Up to 36 days
Participants were enrolled at study sites in the United States.
| Milestone | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| Started | 10 | 10 | 11 | 10 |
| Completed | 9 | 10 | 10 | 10 |
| Not completed | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Participant decision | 1 | 0 | 0 | 0 |
AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state at Day 6.
| hours(h)*nanograms per milliliter(ng/mL) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau | 94.6 ± 29.8 | 112 ± 32.6 | 1880 ± 642 | 1810 ± 560 |
Cmax is defined as the maximum observed concentration of drug at steady state at Day 6.
| ng/mL | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| PK Parameter for BLV: Cmax ss | 15.0 ± 8.11 | 14.6 ± 9.35 | 311 ± 110 | 307 ± 156 |
AUC0-24 is defined as the concentration of drug over time between time 0 hour and time 24 hours.
| h*ng/mL | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| PK Parameter for BLV: AUC0-24 | 46.5 ± 13.3 | 53.4 ± 6.77 | 843 ± 480 | 876 ± 458 |
Cmax is defined as the maximum observed concentration of drug.
| ng/mL | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| PK Parameter for BLV: Cmax | 12.3 ± 4.91 | 13.1 ± 6.49 | 121 ± 86.2 | 146 ± 83.9 |
Tmax is defined as the time (observed time point) of Cmax.
| h | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| Tmax (Day 1) | 1.00 (1.00 to 2.00) | 1.00 (0.500 to 2.00) | 4.00 (1.50 to 6.00) | 4.00 (1.50 to 9.00) |
| Tmax (Day 6) | 1.00 (1.00 to 3.00) | 1.50 (1.00 to 6.00) | 3.00 (2.00 to 4.03) | 3.00 (3.00 to 6.00) |
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| h | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| t1/2 (Day 1) | 2.47 (1.32 to 4.34) | 3.95 (1.20 to 6.66) | 2.86 (1.44 to 14.5) | 3.03 (1.53 to 8.23) |
| t1/2 (Day 6) | 3.98 (2.84 to 8.72) | 4.60 (2.31 to 7.87) | 2.79 (1.46 to 7.47) | 2.75 (1.44 to 3.78) |
CLss/F is defined as the apparent clearance at steady state at Day 6. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.
| milliliters per hour (mL/h) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| PK Parameter for BLV: CLss/F | 29.9 ± 13.4 | 19.1 ± 7.54 | 5.80 ± 1.69 | 6.09 ± 2.22 |
Vss/F is defined as the apparent volume of distribution at steady state at Day 6.
| mL | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| PK Parameter for BLV: Vss/F | 222 ± 175 | 121 ± 69.4 | 24.4 ± 10.7 | 25.0 ± 14.2 |
The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. Cmax is defined as the maximum observed concentration of total BA. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.
| micromoles per liter (µmol/L) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| Cmax (Day 1) | 13.5 ± 8.58 | 8.54 ± 7.02 | 110 ± 50.6 | 121 ± 53.6 |
| Cmax (Day 6) | 48.1 ± 35.4 | 58.2 ± 24.5 | 168 ± 83.4 | 207 ± 52.1 |
The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. AUC0-24 is defined as the concentration of total BA over time between time 0 hour and time 24 hours. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.
| h*µmol/L | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| AUC0-24 (Day 1) | 166 ± 109 | 108 ± 58.8 | 1290 ± 613 | 1450 ± 573 |
| AUC0-24 (Day 6) | 581 ± 442 | 705 ± 324 | 2120 ± 1050 | 2710 ± 669 |
The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. NetAUC is defined as positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.
| h*µmol/L | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| NetAUC (Day 1) | 54.9 ± 40.4 | 66.1 ± 57.6 | 1240 ± 598 | 1400 ± 572 |
| NetAUC (Day 6) | 496 ± 433 | 662 ± 330 | 2060 ± 1020 | 2660 ± 666 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or if the AE onset date was the same as the date of study drug start date then the AE onset time must have been on or after the study drug start time. If the AE onset time was missing when the start dates was the same, the AE was considered treatment emergent.and/or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 40.0 | 20.0 | 27.3 | 30.0 |
A treatment-emergent laboratory abnormality was any value that was outside the reference range at any time post baseline up to and including the date of last study drug dose plus 30 days. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death. Participants with at least a 1 grade increased from baseline for an individual laboratory test where the maximum post baseline laboratory abnormality was grade 1 or higher and grade 3 or higher were reported. The maximum post baseline toxicity grade across all tests for an individual participant was used in analysis.
| percentage of participants | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| Grade 1 or Higher | 100 | 90.0 | 100 | 90.0 |
| Grade 3 or Higher | 50.0 | 0 | 45.5 | 0 |
Collected over All-Cause Mortality: Up to 420 days; Adverse Events: Up to 36 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: BLV 2 mg (Severe RI Group) | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Group A: BLV 2 mg (Matched Control) | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Group B: BLV 10 mg (Severe RI Group) | 0/11 (0%) | 1/11 (9.1%) | 2/11 (18.2%) |
| Group B: BLV 10 mg (Matched Control) | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/10 | 0/10 | 1/11 | 0/10 |
| Event | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) |
|---|---|---|---|---|
| EosinophiliaBlood and lymphatic system disorders | 1/10 | 0/10 | 0/11 | 0/10 |
| NeutropeniaBlood and lymphatic system disorders | 1/10 | 0/10 | 0/11 | 0/10 |
| Vessel puncture site haemorrhageGeneral disorders | 1/10 | 0/10 | 0/11 | 0/10 |
| Urinary tract infectionInfections and infestations | 1/10 | 0/10 | 0/11 | 0/10 |
| Alanine aminotransferase increasedInvestigations | 0/10 | 0/10 | 0/11 | 1/10 |
| Lipase increasedInvestigations | 1/10 | 0/10 | 0/11 | 0/10 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/10 | 0/10 | 0/11 | 1/10 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/10 | 1/10 | 0/11 | 0/10 |
| HeadacheNervous system disorders | 0/10 | 1/10 | 1/11 | 1/10 |
| DysmenorrhoeaReproductive system and breast disorders | 0/10 | 0/10 | 0/11 | 1/10 |
The Safety Analysis Set included all participants who took at least 1 dose of study drug BLV.
| Age, Continuous(years) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) | Total |
|---|---|---|---|---|---|
| Mean | 59 ± 15.1 | 55 ± 10.6 | 63 ± 11.1 | 57 ± 10.6 | 59 ± 11.9 |
| Age, Customized(Participants) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) | Total |
|---|---|---|---|---|---|
| Between 18 and 65 years | 6 | 9 | 5 | 8 | 28 |
| >=65 years | 4 | 1 | 6 | 2 | 13 |
| Sex: Female, Male(Participants) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) | Total |
|---|---|---|---|---|---|
| Female | 4 | 4 | 3 | 3 | 14 |
| Male | 6 | 6 | 8 | 7 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 8 | 8 | 31 |
| Not Hispanic or Latino | 3 | 2 | 3 | 2 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 4 | 0 | 6 |
| White | 8 | 10 | 7 | 10 | 35 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Group A: BLV 2 mg (Severe RI Group) | Group A: BLV 2 mg (Matched Control) | Group B: BLV 10 mg (Severe RI Group) | Group B: BLV 10 mg (Matched Control) | Total |
|---|---|---|---|---|---|
| United States | 10 | 10 | 11 | 10 | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in Jul 2024, 16 months.
Results were first posted in Sep 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bulevirtide